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Abstract
Broad-spectrum antimicrobials kill indiscriminately, a property that can lead to negative clinical consequences and an
increase in the incidence of resistance. Species-specific antimicrobials that could selectively kill pathogenic bacteria without
targeting other species in the microbiome could limit these problems. The pathogen genome presents an excellent target
for the development of such antimicrobials. In this study we report the design and evaluation of species-selective peptide
nucleic acid (PNA) antibacterials. Selective growth inhibition of B. subtilis, E. coli, K. pnuemoniae and S. enterica serovar
Typhimurium in axenic or mixed culture could be achieved with PNAs that exploit species differences in the translation
initiation region of essential genes. An S. Typhimurium-specific PNA targeting ftsZ resulted in elongated cells that were not
observed in E. coli, providing phenotypic evidence of the selectivity of PNA-based antimicrobials. Analysis of the genomes of
E. coli and S. Typhimurium gave a conservative estimate of .150 PNA targets that could potentially discriminate between
these two closely related species. This work provides a basis for the development of a new class of antimicrobial with a
tuneable spectrum of activity.
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Introduction
Treatment of bacterial infections with antimicrobial drugs has
been clinically effective for over six decades. However, the rise of
antimicrobial resistance threatens to limit options for the treatment
of life-threatening microbial diseases [1]. Broad-spectrum antibi-
otics allow empirical usage for the rapid treatment of fulminate
microbial infections, but have been shown to disrupt the
microbiome, which can result in colonization of pathogenic
microbes [2,3], increase susceptibility to disease [4,5], and select
for resistance mechanisms in non-target species that are readily
transferred to pathogenic species [6,7]. Recent findings demon-
strating the importance of the microbiome in host health have led
to a growing interest in possibilities to use pathogen or microbiota-
targeted therapies to eliminate individual strains of single species
[8]. One approach is silencing of essential genes using antisense
mechanisms. Exogenously delivered antisense DNA oligonucleo-
tides, designed to bind to specific mRNA sequences, have been
demonstrated to be effective against bacterial targets [9,10].
Peptide Nucleic Acid (PNA) and Phosphorodiamidate Morpholino
(PMO) oligomers targeted to the translation initiation region (TIR)
of essential mRNAs are bactericidal and have been successfully
applied to a number of different species [11–14]. Bactericidal
PNAs/PMOs are typically 10 bp in length and are more sensitive
to target mismatches than equivalent DNA oligonucleotides [15],
properties that make them highly suited to species discrimination.
In this study we tested the hypothesis that the selective binding
properties of peptide-PNA antimicrobials can be exploited to
selectively target certain species in mixed culture based on
sequence differences in the translation initiation region of essential
genes. A representative Gram-positive bacterium (Bacillus subtilis)
and three Gram-negative bacteria (Klebsiella pneumoniae, Salmonella
Typhimurium and Escherichia coli) were chosen as a mix-species
model in this study. We report, for the first time, that peptide-
PNAs can form the basis of a single class of antimicrobial with a
tuneable spectrum of activity.
Results
Peptide-PNA mediated growth inhibition and
species-selectivity
The four bacterial species were chosen as they have all been
reported to be susceptible to antisense antibiotics [12,14–16]. The
parameters used in the design of species-selective peptide-PNAs
resulted in a number of potential gene targets that could be used
for species-selective growth inhibition. The following criteria were
used for the design of species-selective peptide PNAs: 1) target
gene is essential and homologues are present in all four species
used in this study; 2) the translation initiation region (TIR) of the
mRNA had at least two base-pair differences between species (see
below); 3) the TIR sequence was amenable to the design of
peptide-PNAs with low melting temperatures; 4) where possible,
off-target sites within and between species were not in the TIRs of
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essential genes; and 5) evidence that gene silencing of the target
and/or inhibition of its cognate protein is growth inhibitory. We
have previously shown that murA and ftsZ are sensitive targets for
peptide-PNA mediated growth inhibition [17], both genes were
identified in this study as potential targets for species-selective
peptide-PNAs, and thus, were selected for further study. Two
base-pair mismatches were selected, as PNAs with one base-pair
mismatch may bind to the target, but with reduced affinity [15];
peptide-PNAs with one base-pair mismatch to their target sites
have shown approximately 33% increase in MIC (Liam Good,
unpublished). This is in agreement with the design parameters
suggest by Dryselius et al. [18] in which they suggest 1-bp
mismatches within the TIR of off-target genes should be avoided.
The peptide-PNAs designed in this study were assayed for their
antibacterial activity against both target and non-target species.
The previously reported En108 peptide-PNA (called Ec108 in
[17]) was used as a control to test the feasibility of species-
selectivity at a broad taxonomic level; E. coli, K. pneumoniae and S.
Typhimurium (Gram-negative, Enterobacteriaceae) have identical
acpP TIRs and thus all three species should be susceptible to
En108, while the acpP TIR of Bacillus subtilis (Gram-positive,
Bacillaceae) has six base-pair mismatches and should be resistant
to En108. Antibacterial assays with En108 proved this to be the
case; En108 had an MIC of 1.2, 0.4 and 0.3 mM for E. coli, K.
pneumoniae and S. Typhimurium respectively (Table 1), and had no
detectable antibacterial activity against B. subtilis at concentrations
of up to 20 mM (data not shown). Similarly, the species-selective
PNAs for B. subtilis, K. pneumoniae and S. Typhimurium were only
antibacterial to the intended species (Figure 1A). The E. coli-
selective Ec1000 was unexpectedly cross-reactive with S. Typhi-
murium (discussed below). In all cases treatment with non-specific
PNAs resulted in increased, but statistically insignificant (standard
error P.0.05), growth. Table 2 shows the analysis of potential
binding sites within the genomes of the target species. Of note is
the difference in MIC between E. coli, K. pneumoniae and S.
Typhimurium when treated with the acpP-targeting En108; the
MIC of this PNA was 3 and 4 fold less in K. pneumoniae and S.
Typhimurium, respectively (Table 1). Analysis of the binding sites
of En108, Kp0001 and Se0001 in the genomes of these species
revealed that En108 likely binds in the TIR region of other
essential genes in K. pneumoniae (mukF and ribH) and S. Typhimur-
ium (yhhM) each with a 1 bp mismatch. This could account for the
decreased MIC in these species, however the relationship is not
straightforward as Se0001 is predicted to bind in the TIR of at
least three other genes determined to be essential in E. coli and S.
Typhimurium (hemK, lnt and rluA) and has an MIC equivalent to
that of En108 in E. coli (Table 1). Furthermore, there is no obvious
relationship between the MIC of a peptide-PNA and the number
of off-targets in the genome of the target species, including those
that bind in the TIRs of both essential and non-essential genes
(Table 2). Reasons for the possible differences between the MICs
of the different peptide-PNAs are discussed below.
Use of species-selective PNAs in mixed culture
To test the selectivity of peptide-PNAs in mixed culture, we first
used reciprocal treatment in two-species culture (Figure 1B). When
mixed cultures of E. coli and K. pneumoniae were treated with
3.2 mM of E. coli-selective Ec1000, after 16 hrs of incubation only
K. pneumoniae was detectable. Untreated control cultures main-
tained both species throughout the incubation period. Reciprocal
treatment of the same mixed culture with 3.2 mM of K. pneumoniae-
specific Kp0001 showed equivalent selectivity. Species-selective
growth inhibition was also observed in mixed culture of K.
pneumoniae and S. Typhimurium treated with 3.2 mM Kp0001 or
2.0 mM Se0001 (Figure 1B). S. Typhimurium was successfully
removed from mixed culture with E. coli when treated with 2.0 mM
Se0001, but reciprocal removal of E. coli could not be achieved
with Ec1000 (see above). Three-species mixed culture of B. subtilis,
K. pneumoniae and S. Typhimurium was used to test the possibility
of specifically targeting either one or two species, with a single
peptide-PNA or a combination of two. Kp0001 and Se0001 both
at 4.5 mM were successfully applied to the three-species mixed
culture; only B. subtilis and S. Typhimurium could be detected
after 16 hrs incubation with Kp0001, and only B. subtilis and K.
pneumoniae after Se0001 treatment (Figure 2). Treatment of the
three-species culture with 3.5 mM En108 resulted in the expected
selective growth inhibition of both enteric species, with only B.
Table 1. Properties of peptide-PNAs used in this study.
Namea Target Sequence Minimum Inhibitory Concentration (mM)
Expected
specificityb
Target
site Tm
d Reference
B. subtilis E. coli K. pneumonia S. Typhimurium
Bs0001 ftsZ (KFF) 3K-eg-
caacatgcta
4.0 .10 .10 .10 yes 24 to +6 53.5 This study
En108 acpP (KFF) 3K-eg-
ctcatactct
.10 1.2 0.4 0.3 yes 25 to +5 41.5 Goh et al. 2009
Ec1000 murA (KFF) 3K-eg-
ccatttagtt
.10 2.4 .10 3.2 noe 26 to +4 44.0 This study
Kp0001 murA (KFF) 3K-eg-
tccattgatt
.10 .10 2.5 .10 yes 25 to +5 46.8 This study
Se0001 murA (KFF) 3K-eg-
tccattattg
.10 .10 .10 1.2 yes 25 to +5 43.5 This study
Se0002 ftsZ (KFF) 3K-eg-
aacataatct
.10 .10 .10 2.5 yes 25 to +5 46.1 This study
aCode refers to predicted species-specificity Bs = B. subtilis, Ec = E. coli, En = Enterobacteriaceae, Kp = K. pneumonia, Se = S. enterica Typhimurium.
bIndicates if specificity based on bioinformatic prediction was observed.
cTarget is shown as positions of nucleotides relative to the start codon.
dThermal stability of PNA/DNA duplex.
eEc1000 lacked predicted specificity, see text for details.
doi:10.1371/journal.pone.0089082.t001
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subtilis detectable after 16 hrs. Combined use of Kp0001 and
Se0001, at 4.5 mM each was also able to specifically remove K.
pneumoniae and S. Typhimurium from the mixed culture, however
there was a significant difference in the final B. subtilis CFU count
between the En108 and dual Kp0001/Se0001 treated cultures.
Mixed culture experiments with four species were not attempted in
this study, however the potential of peptide-PNAs as species-
selective antibacterial compounds is highlighted by a comparison
of all possible species combinations for the four species tested in
this study, alongside the antibiotic spectrum of the peptide-PNAs
and twenty known antibiotics (Figure S1 in Information S1).
Only peptide-PNAs are capable of species-selective growth
inhibition for the three Gram-negative species. For these species,
there are six possible outcomes for species-selective antibacterial
treatment of two-species mixed cultures. Treatment with the
twenty antibiotics assessed in this study (Table S1 in Information
S1), could theoretically achieve four of these outcomes (all
combinations except those requiring inhibition of E. coli or K.
pneumoniae in combination with S. Typhimurium). Use of peptide-
PNAs Ec1000, Se0001 and Kp0001 enabled five of the possible
outcomes; unexpected cross-reactivity of Ec1000 prevented
selective inhibition of E. coli in combination with S. Typhimurium.
However, it is very likely that evaluation of other E. coli-selective
peptide PNAs would be able to rectify this result (see below).
Furthermore, of the known antibiotics, only streptomycin could
select between E. coli and S. Typhimurium. This would not be the
case for most strains of E. coli as strain DH10B has an rpsL
mutation that confers resistance to streptomycin. Unlike the
peptide-PNAs, in mixed culture experiments with three species
(Figure 2), no combination of the known antibiotics would be able
to selectively kill any of the Gram-negative species tested without
killing B. subtilis.
Peptide-PNA mediated discrimination of E. coli
and S. Typhimurium
The observation that Ec1000 was antibacterial to the non-target
S. Typhimurium led us to use a comprehensive genomic analysis
to determine the number of potential targets that could be used to
design peptide-PNAs that would discriminate between these two
closely related species. For the purposes of defining potential
discriminatory target sites, we allowed for 1 bp mismatch
difference between the target site of S. Typhimurium and E. coli;
while 1 bp mismatch is not likely to be sufficient to prevent
binding, differences in gene silencing activity may be sufficient, in
some cases, to enable the development of peptide-PNAs that
would be selectively antibacterial to S. Typhimurium. Three
separate BLAST analyses were done: 1) TIR sequences of genes
described as essential in S. Typhimurium against the TIRs of E.
coli essential genes; 2) TIRs of S. Typhimurium genes described as
essential in E. coli, against TIRs of E. coli essential genes and 3) the
TIRs of E. coli essential genes against TIR sequences of genes
described as essential in S. Typhimurium (Tables S2–4 in
Information S1). Using the essential genes of S. Typhimurium
from the DEG database, and the 25 to +5 TIR region we
identified 113 genes that could serve as targets for peptide-PNAs
that would be selectively antibacterial to S. Typhimurium over E.
coli (Table S2 in Information S1). Of these, 68 genes had
orthologues not identified as essential in E. coli, 34 did not have
orthologues in E. coli and of the 11 genes that had essential
orthologues in E. coli, 5 of these had TIR sequences with .2 bp
mismatches. The fact that peptide-PNA Se0001, was selectively
antibacterial for S. Typhimurium, and designed to target a gene
not reported to be essential in S. Typhimurium indicates that
orthologues of genes that are identified as essential in E. coli are
likely to be essential in S. Typhimurium. Furthermore, E. coli genes
have been identified as essential by failure to construct a specific
knockout, whereas those of S. Typhimurium were identified by
trapping lethal insertions [19].
We applied the bioinformatic screening technique described
above to identify peptide-PNAs that would discriminate between
S. Typhimurium and E. coli using the essential genes of E. coli as
the query sequences. This analysis identified a further 93
orthologous genes that could potentially act as targets for
Figure 1. Species-selective antibacterial peptide-PNAs in
axenic and two-species mixed culture. E. coli (dark grey), K.
pneumoniae (white) and S. Typhimurium (light grey). All cultures were
incubated for 16 hrs. A) axenic cultures of the species were treated with
E. coli- specific Ec1000 at 3.2 mM, K. pneumoniae-specific Kp0001 at
3.2 mM and S. Typhimurium-specific Se0001 at 2.0 mM. Asterisks indicate
species-selective growth inhibition of E. coli, K. pneumoniae and S.
Typhimurium respectively. B) Two-species mixed cultures treated with
peptide-PNAs as above. The control cultures show the relative
proportion of the two species without treatment, the two treatments
to the left of the control represent the same mixed culture treated with
a peptide-PNA. Black arrows indicate non species-selective growth
inhibition of S. Typhimurium by Ec1000. Error bars are standard error for
biological replicates (n=3).
doi:10.1371/journal.pone.0089082.g001
Species-Specific Antimicrobials
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discriminatory peptide-PNAs (Table S3 in Information S1). Of
these, 47 genes had TIRs with.2 bp mismatches between the two
species, from which ftsZ was chosen for further study. This target
was chosen for the reasons given above, and because gene
silencing of ftsZ should result in a cell filamentation phenotype that
would enable microscopic evaluation of the specificity of the
peptide-PNA in mixed culture. DsRed-labelled E. coli AC01, and
GFP-labelled S. Typhimurium AC02 were exposed to peptide-
PNA Se0002 at concentrations #5 mM. E. coli AC01 was
unaffected by Se0002 at all concentrations tested, whereas S.
Typhimurium growth was inhibited at 1.25 mM (0.56MIC), with
a lag phase ca. 7.5 hrs longer than that of the untreated sample
(Figure 3A). Growth of S. Typhimurium observed in Se0002-
treated cultures after 10. 5 hrs was not due to the generation of
spontaneous resistance mutants, as samples of cells taken after
14 hrs of incubation, passaged into fresh media containing the
same concentration of Se0002, exhibited identical growth kinetics
to the parent culture. Growth is more likely due to the effective
concentration of Se0002 falling below that required to inhibit
translation of ftsZ; caused by the peptide-PNA accumulating in
non-growing cells, adsorbing to the plastic of the well, or
proteolysis of the carrier peptide. Mixed cultures of E. coli AC01
and S. Typhimurium AC02 prepared as above, treated with
1.25 mM of Se0002 were sampled after 6 hrs of growth and were
observed by fluorescence microscopy (Figure 3B). As predicted, E.
coli AC01 treated with Se0002 had an identical phenotype to
untreated controls, whereas S. Typhimurium AC02 cells displayed
a distinct filamentous phenotype only upon treatment with
Se0002. This phenotype is consistent with previous studies using
anti-ftsZ peptide-PNAs in E. coli [17]. These results, and those of
the mixed culture experiments detailed above, prove that it is
possible to employ antisense-based molecules as species-selective
antimicrobial agents in mixed culture.
Discussion
The aim of this study was to test the hypothesis that peptide-
PNAs can be applied as species-selective antimicrobial com-
pounds. Using mixed cultures, we demonstrate the feasibility of
using PNAs as species-selective antisense antibacterials. Antibac-
terial peptide-PNAs evaluated against B. subtilis, E. coli, K.
pneumoniae and S. Typhimurium, both in single and mixed cultures,
with the exception of Ec1000, displayed detectable antibacterial
activity against the intended species only. Peptide-PNA treatment
Figure 2. Species-selective antibacterial peptide-PNAs in three-
species mixed culture. B. subtilis (dark grey), K. pneumoniae (white)
and S. Typhimurium (light grey) in mixed culture were separately
treated with Ec108 at 3.5 mM, Kp0001 or Se0001 at 4.5 mM or by
combined treatment of Kp0001 and Se0001 both at 4.5 mM. All cultures
were incubated for 16 hrs. Selective inhibition of either K. pneumoniae
or S. Typhimurium individually or together, achieved with the peptide-
PNAs, could not theoretically be achieved with any combination of the
twenty known antimicrobial compounds tested in this study. Error bars
as above.
doi:10.1371/journal.pone.0089082.g002
Table 2. PNA binding site analysis in target species.
Species PNA
No. off
targetsa Off Targets within TIR
b of gene
No. essential (gene)c No. non-essential (gene)
E. coli En108 128 0 11 (araH, arpB, cadB, gpp, ssuE, ugpQ, upp, yagW, yhjG, yodC, yqjF)
K. pneumoniae En108 143 2 (mukFd,e, ribHd,f) 5 (gppA, kpn_00790, kpn_01124, kpn_04794, nlpA)
S. Typhimurium En108 138 1 (yhhMd) 14 (dps, hycE, pmgI, STM0566, STM0762, STM1698, STM2137, STM2481, STM3085, STM4218,
thiJ, upp, ydcY, ygaC)
E. coli Ec1000 201 2 (lntd,f, rpsNd,f) 11 (elaD, hypF, mrcA, ppsR, rhsD, ybfD, ydcC, yfbM, yhaJ, yhhI, yjgH)
S. Typhimurium Se0001 320 6 (aspCf, hemKd,e,f, lntd,f, nuoIf,
purDf, rluAd,f)
8 (fucA, ppiC, sodA, STM2343, STM2903, yajB, ybdF, yebB)
S. Typhimurium Se0002 311 0 11 (celC, t0363, t0453, t1718, t2652, t4467, tdcE, umuC, yacK, yadI, ybaB)
K. pneumoniae Kp0001 157 3 (ispAd,f, rpsNd,f, topBe) 3 (KPN_02027, KPN_04368, rhaT)
B. subtilis Bs0001 104 0 4 (yabQ, yeeG, yruI, yvyE)
aincludes sites with # 1base-pair mismatch with PNA.
bTranslation Initiation Region.
cidentified by BLAST searching of the Database of Essential Genes.
dessential in E. coli.
eessential in S. Typhimurium.
fessential in other prokaryotes.
ND Not determined.
doi:10.1371/journal.pone.0089082.t002
Species-Specific Antimicrobials
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of mixed cultures enabled selective growth inhibition that, in
theory, could not be achieved using the twenty antibiotics
evaluated in this study. Our findings suggest that PNAs are
candidates for narrow-spectrum antimicrobials. For species-
selectivity, 16S rRNA would appear to be a logical candidate.
However, while peptide-PNAs targeted to 16S rRNA have been
demonstrated to be bactericidal and sequence selective [11,20],
prior to this study, species selectivity has not been observed and
may be difficult to achieve due to sequence conservation within
functional regions of 16S rRNA.
The observation that En108 has different activity in three
closely related species might be explained by binding of the PNA
to the TIRs of 1-base mismatched off-target essential genes
simultaneously in K. pneumoniae and S. Typhimurium, and only the
intended target in E. coli. Antisense-based antimicrobials have
been demonstrated to show greater growth inhibitory activity
when the expression of multiple essential genes are simultaneously
inhibited [9]. This may also explain the weak synergistic effect of
Kp0001 and Se0001 when used in combination in cultures of B.
subtilis. In addition, there may be mechanistic differences in the
gene silencing itself (binding efficacy, Tm differences caused by
mismatches, and location of the off-target relative to TIR) or
differences in the stringency of requirement for the target and off-
target genes, i.e. a small reduction in the mRNA pool of the two
off-targets in K. pneumoniae may be better tolerated than that of the
off-targets in S. Typhimurium [17]. Differences in the susceptibil-
ity of the three species to En108 may also be explained by uptake
efficiency; the transporter protein SbmA has recently been
identified as required for PNA uptake in E. coli [17,21]. The
authors show that the peptide-PNA crosses the outer membrane,
followed by protease degradation of the peptide carrier in the
periplasmic space, and SbmA-mediated transport of the free PNA
across the inner membrane. Degradation of the peptide carrier,
may account for the slight increase in growth observed in non-
target species. It is interesting that the E. coli sbmA gene shares 86%
and 92% similarity to its orthologues in K. pneumoniae and S.
Typhimurium respectively; determining if SbmA orthologues have
different PNA uptake kinetics may aid predicting the likely
susceptibility of species to PNAs. B. subtilis is not reported to have a
homologue of SbmA. However, it is sensitive to bleomycin, a
glycopeptide transported by SbmA into the cytoplasm of E. coli.
Homology searching of the B. subtilis genome using the SbmA
sequence from E. coli, reveals a number of ABC-type transporters,
such as YgaD (Figure S2 in Information S1) that may perform a
similar function as SbmA. Elucidation of the mechanism of PNA
uptake in Gram-positive species will aid in their development as
antibacterial compounds.
The finding that PNA Ec1000, designed to silence the murA
gene of E. coli, was antibacterial to S. Typhimurium was
unexpected. The parameters described for the design of species-
selective PNAs theoretically selects for PNAs to the TIRs of
essential genes in only the target species. An analysis of the binding
sites (allowing for 1 bp mismatch) for Ec1000 in S. Typhimurium
shows that it binds intragenically to a number of essential genes
(alaS, fusA, hemE and rplF) that are reported to be toxic upon
overproduction [22]; peptide-PNAs can significantly elevate gene
expression when binding downstream of the TIR [18]. It is also
possible that the Ec1000 PNA may bind to a non-coding RNA,
which can act as regulatory elements [23]. While we could not
identify any potential binding between Ec1000 and known non-
coding RNAs in S. Typhimurium [24], there may be as yet
unidentified non-coding RNAs that are transcribed from, or
interact with, intergenic Ec1000 binding sites; disruption of a RNA
antitoxin is one possible mechanism that would lead to bactericide
[25]. The elucidation of the mechanism responsible for Ec1000-
induced growth inhibition in S. Typhimurium is required for the
continued development of species-selective antibacterial PNAs;
understanding of the mechanism will enable the design parameters
of peptide-PNAs to be modified to exclude likely off-target effects
and/or identification of new targets for gene-silencing antimicro-
bials.
Comparative genomics between sensitive and resistant species,
qRT-PCR [17] and the introduction of point mutations within
putative targets could be applied to identify the cause of the off-
target selectivity in S. Typhimurium. While the unexpected
activity of Ec1000 prevented its use as an E. coli species-selective
peptide-PNA, our in-silico analysis, and the identification of E. coli-
specific TIRs (Table S4 in Information S1) suggest that finding
targets that are amenable for discriminating E. coli from closely
related species is readily achievable. There are 46 targets, in the
25 to +5 TIR region of essential genes in E. coli, that have .2 bp
Figure 3. S. Typhimurium-selective growth inhibition. Peptide-
PNA Se0002 was designed to target the 25 to +5 region of the
translational initiation region (TIR) of ftsZ in S. Typhimurium. Se0002 has
2 base pair mismatches in the TIR of ftsZ in E. coli. (A) Growth curve
analysis of Se0002 in pure culture. E. coli growth in the presence of
1.25 mM Se0002 (solid line) was identical to that of untreated controls
(not shown). S. Typhimurium growth was inhibited in the presence of
1.25 mM of Se0002 (dotted line) relative to the untreated control
(dashed line). Growth in the treated samples after 10 hrs was not due to
resistance (see text for details). (B) Mixed cultures of GFP-labeled S.
Typhimurium AC02 and DsRed-labeled E. coli AC01 were treated with
1.25 mM Se0002; and imaged by fluorescence microscopy after 6 hrs of
incubation. The filamentous growth phenotype was only observed in S.
Typhimurium AC02 and is consistent with silencing of ftsZ expression.
doi:10.1371/journal.pone.0089082.g003
Species-Specific Antimicrobials
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mismatches with orthologs in S. Typhimurium (Table S3 in
Information S1). The in silico approach was applied in the
successful design of Se0002, and thus a peptide-PNA raised to the
same target in E. coli, will likely discriminate E. coli for S.
Typhimurium. Nevertheless, the possibility for cross-reactivity to
occur in bacterial species that are part of the microbiome cannot
be excluded, as microbiomes are dynamic and unique to host
species. The availability of in-depth microbiome sequencing will
aid in the design of species-selective PNAs through exhaustive
prediction of binding sites in all species of the microbiome.
Relative to currently used antibiotics, PNAs provide new
opportunities for the design of ultra-narrow-spectrum antimicro-
bials, where the primary target is dictated by the nucleic acid
sequence. Of course, perfectly specific pathogen targeting may
never be possible, but the results presented here show clearly that
large improvements are possible over currently used drugs, thus
enabling the reduction of antibiotic resistance and secondary
infection, through the reduction of off-target antibiosis. Finally,
while the mode of action of peptide-PNA antimicrobials is well
understood [11,15,26,27], differences in uptake of the peptide-
PNA, species sensitivity and the effect of non-target binding
remain important areas for future experimentation.
Materials and Methods
Bacterial strains and growth conditions
A list of the strains used in this study is given in Table 3. All
strains were grown in Miller’s modified Luria broth (MMLB;
Sigma-Aldrich, UK) with constant shaking (200 rpm) at 37uC. For
mixed-culture growth, MMLB was inoculated with 16104 CFU/
ml; the proportion of each species needed to give reproducible
species counts after 16 h of growth at 35uC was experimentally
determined (Table S5 in Information S1).
Design of species-specific peptide PNAs
General guidelines for the design of antibacterial peptide-PNAs
are described elsewhere [11,15,26,27]. Criteria used for the design
of species-specific peptide-PNAs are described in the results
section. The Database of Essential Genes [28] and BLAST [29]
were used to identify any essential gene homologues present in all
four species used in this study. The Artemis program [30] was used
to extract twenty base-pairs (210 to +10 bases relative to the start
codon) of the TIRs from the genome sequences of Bacillus subtilis
[31], Escherichia coli DH10B [32], Klebsiella pneumoniae and Salmonella
enterica serovar Typhimurium LT2 [19] (GenBank accession
numbers: AL009126; CP000948; CP000647; and AL513382
respectively). The 20 bp TIRs from gene homologues were
aligned in Clustal X version 2.0 [33] and the number of base-
pair mismatches between species was determined. The predicted
thermal stability (Tm) of PNA/DNA duplexes was determined
according to formula of Giesen et al. 1998 [34]. A genomic
analysis of the possible binding sites of the PNAs within their target
species was conducted in Artemis, using a cut-off of greater than
2 bp mismatches. Secondly, to comprehensively examine the
number of potential antibacterial PNAs that could be used to
discriminate between two closely related species, a semi-automated
method was employed: genome sequences were used to identify
the start codon positions of essential genes from E. coli DH10B and
S. Typhimurium LT2. A custom PERL script was used to extract
the 25 to +5 bases relative to the start codon of each gene. The
10 bp sequences were used for an all-against-all comparison using
standalone BLAST [29,35] to identify the TIRs of essential genes
that were amenable to the design of species specific PNAs. The
peptide-PNAs used in this study and their properties are listed in
Table 1.
Antimicrobial susceptibility and peptide-PNA minimal
inhibitory concentration (MIC) testing
Strains were tested with twenty different antibiotic disks (Oxoid,
UK) representing the major classes of antimicrobial compounds.
Tests were done according to the standardized disc susceptibility
testing method of the British Society for Antimicrobial Chemo-
therapy [36,37]. The minimum inhibitory concentration (MIC) of
the peptide-PNA conjugants were determined using a method
modified from Hacek et al [38] and Friedman et al [39]: Peptide-
PNA conjugants, obtained as lyophilized powder (Panagene,
Korea), were dissolved in ddH20. MIC assays were performed in
an ultra low-bind (Costar, UK) polystyrene 96-well plate format in
a final volume of 150 ml MMLB. An extended gradient of peptide-
PNA concentrations was created by combining five sets of twofold
serial dilutions from four starting concentrations (10, 4.8, 3.2 and 3
and 2 mM); giving 55 final peptide-PNA concentrations which
extended over five rows of the 96-well plate. All cultures were
incubated at 35uC for 16 h without shaking or agitation. Each
peptide-PNA MIC calculation was performed in triplicate, each
Table 3. Bacterial strains used in this study.
Strain Source Genotype Characteristic
Bacillus subtilis subsp. subtilis 168 ATCCa 23857 trpC2 Genome sequenced strain
Escherichia coli DH10B Invitrogen F2 endA1, recA1, galE15, galK16, nupG, rpsL,
DlacX74, W80lacZDM15, araD139, D(ara,leu)7697,
mcrA, D(mrr-hsdRMS-mcrBC), l2
Genome sequenced strain, parent of E.
coli AC01
E. coli AC01 This study As above, pDsRed-Express2 Expression of DsRed fluorescent protein
Klebsiella pneumoniae subsp. pneumoniae ATCC 700721 n/a Genome sequenced strain
Salmonella enterica serovar Typhimurium LT2 SGSCb 1412 n/a Genome sequenced strain
S. Typhimurium LT2 substr JR501 SGSC 1593 hsdSA29, hsdSB121, hsdL6, metA22, metE55,1 trpC2,
ilv-452, H1-b, H2-e,n,x (cured of Fels 2), fla-66, nml,
rpsL120, xyl-404, galE719
Restriction-deficient, modification-
proficient cloning strain of S.
Typhimurium LT2, parent of S.
Typhimurium AC02
S. Typhimurium AC02 This study As above, pGFPuv Expression of green fluorescent protein
aAmerican Type Culture Collection.
bSalmonella Genetic Stock Center.
doi:10.1371/journal.pone.0089082.t003
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replicate representing a different starting colony. Mixed-culture
experiments were conducted as above with a 16104 CFU/ml
starting inoculum. For growth curve analysis, 200 ml cultures were
grown in a BioTek PowerWave HT spectrophotometer, under
constant agitation at 37uC in a 96-well plate covered with a
breathable film. Growth (OD550) was monitored every 5 mins,
each experiment was performed in triplicate.
Microscopy
Cells prepared for fluorescence imaging were grown in a
BioTek PowerWave HT spectrophotometer as above. After six
hours 10 ml of culture was removed, washed and resuspended in 1
X PBS by centrifugation (13, 0006g). Cells were applied to an
agarose pad [40] and viewed using an epifluorescence Leica
DMRB microscope. An EXi Aqua CCD camera (QImaging) and
Image Pro Plus (MediaCybernetics) were used for image
acquisition and processing.
Species identification
In mixed-culture experiments, colonies on MMLB plates were
identified using a combination of phenotypic and genotypic
properties. In order to rapidly identify species post peptide-PNA
treatment, we designed a species-specific PCR-based identification
method. Primer sets for peptide deformylase (def) were designed
that yielded different sized amplicons for each species: B. subtilis
(352 bp), E. coli (394 bp), K. pneumoniae (231 bp) and S. Typhimur-
ium (280 bp) (see Table S6 in Information S1). All colonies were
picked from the plates with the most countable dilution (30–50 cfu
per plate) and used directly for colony multiplex PCR in 10 ml
reaction volumes according to the simplified method of Menossi et
al. [41]. Colonies were identified using standards prepared from
pure cultures. Furthermore, in the three-species mixed-culture
experiments, colonies were identified using the colony PCR
protocol with 16S rRNA gene primers. The sequences of both
strands of the resulting amplicons were determined with the
BigDye (version 3.1) cycle sequencing kit and a 3730 DNA
analyzer (Applied Biosystems, UK). Species identity was confirmed
using the SEQMATCH function of the Ribosomal Database
Project [42]
Supporting Information
Information S1 Figure S1. Venn diagram of the fifteen possible
species combinations (lettered A–O) in a theoretical bacterial
community composed of the four species used in this study. The
key on the right indicates the antimicrobial agent that would result
in the bactericide of the desired species target(s). Peptide-PNAs are
in bold. Only the peptide-PNAs designed in this study are capable
of species-specific bactericide for individual (C and D) and mixed
(M) Gram-negative species. * Peptide-PNA (Ec1000) was non-
specific, but a number of E. coli- specific PNAs were designed
(Table S4–6 in Information S1) that have yet to be evaluated.
Figure S2. The predicted structures of the E. coli PNA transporter
protein SbmA (pink) and YgaD (blue) of B. subtilis. Structures were
predicted using the I-TASSER platform [1]. YgaD was identified
by homology searching using HHPred [2] with SbmA as the input
sequence. Protein sequences were aligned and rendered by
PyMOL [3]. Table S1. Antibiotic susceptibility of strains used in
this study. Table S2. S. Typhimurium-specific PNAs. Table S3. S.
Typhimurium-specific PNAs designed using essential genes from E.
coli. Table S4. E. coli-specific PNAs. Table S5. Number of cells
used for inoculation of mixed culture. Table S6. Oligonucleotides
used in this study.
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